

CORRECTION

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

Janaki Amin, Mark A. Boyd, Nagalingeswaran Kumarasamy, Cecilia L. Moore, Marcello H. Losso, Chidi A. Nwizu, Lerato Mohapi, Stephen J. Kerr, Annette H. Sohn, Hedy Teppler, Boris Renjifo, Jean-Michel Molina, Sean Emery, David A. Cooper, SECOND-LINE

The group author, SECOND-LINE, was omitted from the author byline and should be listed as the fifteenth author. Please see the full list of contributing authors, as well as their full authorship contributions in the Acknowledgements section of the published article.

Reference

1. Amin J, Boyd MA, Kumarasamy N, Moore CL, Losso MH, Nwizu CA, et al. (2015) Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLoS ONE 10(2): e0118228. doi: [10.1371/journal.pone.0118228](https://doi.org/10.1371/journal.pone.0118228) PMID: [25723472](https://pubmed.ncbi.nlm.nih.gov/25723472/)



OPEN ACCESS

Citation: Amin J, Boyd MA, Kumarasamy N, Moore CL, Losso MH, Nwizu CA, et al. (2015) Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLoS ONE 10(10): e0140623. doi:10.1371/journal.pone.0140623

Published: October 9, 2015

Copyright: © 2015 Amin et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.